The present invention relates to an immune modulator comprising (i) a compound of formula I or a pharmaceutically acceptable salt or solvate thereof:

##STR00001##

wherein X and Y are independently selected from —CH.sub.2— and —O—, preferably are —CH.sub.2—; Z is N or C, preferably is N; m is an integer of from 0 to 3, preferably is 0; n is an integer of from 1 to 3, preferably is 1; R.sup.1 is, optionally substituted, C.sub.5-C.sub.6 cycloalkyl or aryl: R.sup.2 is, optionally substituted, aryl or heteroaryl; R.sup.3 and R.sup.4 are —H, or R.sup.3 and R.sup.4 together form a —CH.sub.2—CH.sub.2— bridge; R.sup.5 and R.sup.7 are independently selected from alkyl, preferably methyl and isopropyl; and in case Z is N, R.sup.6 is absent, or, in case Z is C, R.sup.6 together with R.sup.5 forms a —CH═CH—CH═CH— bridge; and/or (ii) a C—C chemokine receptor type 5 (CCR5) inhibitor, for use in treating and/or preventing pneumonia, sepsis, and/or coronavirus infection in a subject, and to methods, uses, kits an devices related thereto.

A novel composition for regenerating a cartilage has been demanded, which can achieve a good effect of regenerating a hyaline cartilage that is a nearly normal cartilage without requiring the use of any transplanted cell. The present invention provides a composition for regenerating a cartilage, wherein (a) a monovalent metal salt of low endotoxin alginic acid and (b) SDF-1 are used in combination.

A pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein, use of the pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases, and use of the pharmaceutical composition for immunomodulation.

A pharmaceutical composition comprising at least one antibody and at least one mesenchymal stromal cell-derived protein, use of the pharmaceutical composition for treating immunological diseases, for example alloimmune and autoimmune diseases, and use of the pharmaceutical composition for immunomodulation.

A C—C chemokine receptor 3 (CCR3) peptide analog that exhibits biased antagonism by binding to and inhibiting ligand-mediated signaling and chemotaxis while promoting the internalization and degradation of CCR3 is provided as is a method of using the peptide analog to treat, prevent, or ameliorate one or more symptoms of an eosinophil- or CCR3-mediated disease or condition.

This disclosure is directed to methods of treating a subject with a fibrotic or fibroproliferative disease, comprising administering to the subject a composition comprising an effective amount of an anti-fibrosis agent, e.g., a CXCR4 and/or CXCR7 binding agent, such as CXCL12.

The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.

The present invention concerns methods and compositions for evoking protective immune responses against pathogen infection or cancer. In certain embodiments, the methods and compositions comprise a lymphangiogenesis inducer and an antigen.

The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1α (SDF-1α); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1α. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1α or a polynucleotide codes a protein thereof.

CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.